BG-C0902

BG-C0902 is a bispecific antibody-drug conjugate (ADC) developed by BeOne Medicines for the treatment of advanced solid tumors. It consists of a fully humanized bispecific antibody targeting both the Epidermal Growth Factor Receptor (EGFR) and the Hepatocyte Growth Factor Receptor (MET). The antibody is conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. By simultaneously targeting EGFR and MET, BG-C0902 is designed to overcome resistance mechanisms often encountered with single-target therapies, particularly in tumors where these pathways are co-activated or where one pathway compensates for the inhibition of the other. The drug is currently undergoing Phase 1a/1b clinical evaluation to assess its safety, pharmacokinetics, and preliminary antitumor activity in patients with advanced solid tumors.